Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
2003 1
2011 3
2012 3
2013 7
2014 8
2015 10
2016 8
2017 9
2018 14
2019 23
2020 19
Text availability
Article attribute
Article type
Publication date

Search Results

96 results
Results by year
Filters applied: . Clear all
Page 1
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.
Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, Luke JJ, Gajewski TF. Matson V, et al. Among authors: luke jj. Science. 2018 Jan 5;359(6371):104-108. doi: 10.1126/science.aao3290. Science. 2018. PMID: 29302014 Free PMC article.
Targeted agents and immunotherapies: optimizing outcomes in melanoma.
Luke JJ, Flaherty KT, Ribas A, Long GV. Luke JJ, et al. Nat Rev Clin Oncol. 2017 Aug;14(8):463-482. doi: 10.1038/nrclinonc.2017.43. Epub 2017 Apr 4. Nat Rev Clin Oncol. 2017. PMID: 28374786 Free article. Review.
STING pathway agonism as a cancer therapeutic.
Flood BA, Higgs EF, Li S, Luke JJ, Gajewski TF. Flood BA, et al. Among authors: luke jj. Immunol Rev. 2019 Jul;290(1):24-38. doi: 10.1111/imr.12765. Immunol Rev. 2019. PMID: 31355488 Free PMC article. Review.
WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers.
Luke JJ, Bao R, Sweis RF, Spranger S, Gajewski TF. Luke JJ, et al. Clin Cancer Res. 2019 May 15;25(10):3074-3083. doi: 10.1158/1078-0432.CCR-18-1942. Epub 2019 Jan 11. Clin Cancer Res. 2019. PMID: 30635339 Free PMC article.
Tumor-reprogrammed resident T cells resist radiation to control tumors.
Arina A, Beckett M, Fernandez C, Zheng W, Pitroda S, Chmura SJ, Luke JJ, Forde M, Hou Y, Burnette B, Mauceri H, Lowy I, Sims T, Khodarev N, Fu YX, Weichselbaum RR. Arina A, et al. Among authors: luke jj. Nat Commun. 2019 Sep 2;10(1):3959. doi: 10.1038/s41467-019-11906-2. Nat Commun. 2019. PMID: 31477729 Free PMC article.
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.
Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, Pauschinger M, Gajewski TF, Lipson EJ, Luke JJ. Heinzerling L, et al. Among authors: luke jj. J Immunother Cancer. 2016 Aug 16;4:50. doi: 10.1186/s40425-016-0152-y. eCollection 2016. J Immunother Cancer. 2016. PMID: 27532025 Free PMC article.
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.
Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch L, Chang P, Patel JD, Fleming GF, Moroney J, Sharma MR, White JR, Ratain MJ, Gajewski TF, Weichselbaum RR, Chmura SJ. Luke JJ, et al. J Clin Oncol. 2018 Jun 1;36(16):1611-1618. doi: 10.1200/JCO.2017.76.2229. Epub 2018 Feb 13. J Clin Oncol. 2018. PMID: 29437535 Free PMC article. Clinical Trial.
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.
Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM; Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups. Bedognetti D, et al. Among authors: luke jj. J Immunother Cancer. 2019 May 22;7(1):131. doi: 10.1186/s40425-019-0602-4. J Immunother Cancer. 2019. PMID: 31113486 Free PMC article. Review.
The efficacy of anti-PD-1 agents in acral and mucosal melanoma.
Shoushtari AN, Munhoz RR, Kuk D, Ott PA, Johnson DB, Tsai KK, Rapisuwon S, Eroglu Z, Sullivan RJ, Luke JJ, Gangadhar TC, Salama AK, Clark V, Burias C, Puzanov I, Atkins MB, Algazi AP, Ribas A, Wolchok JD, Postow MA. Shoushtari AN, et al. Among authors: luke jj. Cancer. 2016 Nov 15;122(21):3354-3362. doi: 10.1002/cncr.30259. Epub 2016 Aug 17. Cancer. 2016. PMID: 27533633 Free PMC article. Clinical Trial.
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.
Fong L, Hotson A, Powderly JD, Sznol M, Heist RS, Choueiri TK, George S, Hughes BGM, Hellmann MD, Shepard DR, Rini BI, Kummar S, Weise AM, Riese MJ, Markman B, Emens LA, Mahadevan D, Luke JJ, Laport G, Brody JD, Hernandez-Aya L, Bonomi P, Goldman JW, Berim L, Renouf DJ, Goodwin RA, Munneke B, Ho PY, Hsieh J, McCaffery I, Kwei L, Willingham SB, Miller RA. Fong L, et al. Among authors: luke jj. Cancer Discov. 2020 Jan;10(1):40-53. doi: 10.1158/2159-8290.CD-19-0980. Epub 2019 Nov 15. Cancer Discov. 2020. PMID: 31732494 Free PMC article.
96 results
Jump to page
Feedback